One of the buzzword terms in modern medicine today is “personalized medicine”. Instead of simply matching a drug or treatment to an over-arching disease based on a one-size-fits-all philosophy, as has been done in the past, the move now is to customize treatments, based on a much more detailed understanding of the patient, an understanding made possible by new technologies.

The bottom line is that not all patients are alike, and a given disease can take on remarkably different characteristics depending upon the person affected, potentially requiring significantly different drugs and other treatments. It’s a simple concept, but putting it into practice involves some of the most advanced medical technology available. Patients can seem identical, but can have subtle genetic or other variations that need to be considered for optimum treatment. Sophisticated genetic tests can reveal cell or molecular level factors that can affect medical decisions, but there are also other ways to identify what’s going on in the human body at the deepest levels.

FluoroPharma Medical is a developer of advanced tracer chemicals needed to make positron emission tomography (PET) an effective analytic tool. PET scans depend upon having the proper tracer chemicals to integrate with and highlight the internal process to be evaluated. Tracer chemicals are the key to unlocking PET’s remarkable potential.

FluoroPharma’s two lead products are CardioPET, used for the assessment of myocardial metabolism, and BFPET, used for the assessment of blood flow in CAD patients. They are also developing VasoPET, to be used for the detection of vulnerable plaque in CAD patients. Studies have shown PET imaging to be cost-effective for CAD management. It can result in a 50% reduction in the use of coronary arteriography and CABG, a 30% reduction in CAD management costs, and excellent short-term patient outcomes, compared with conventional SPECT imaging.

For more information, visit www.FluoroPharma.com

Let us hear your thoughts below: